• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经导管三尖瓣介入治疗:现状与未来展望。

Transcatheter tricuspid valve interventions: Current status and future perspectives.

作者信息

Alperi Alberto, Almendárez Marcel, Álvarez Rut, Moris Cesar, Leon Victor, Silva Iria, Hernández-Vaquero Daniel, Pascual Isaac, Avanzas Pablo

机构信息

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain.

Cardiac Pathology Department, Health Research Institute of Asturias (Instituto de investigación Sanitaria del Principado de Asturias), Oviedo, Spain.

出版信息

Front Cardiovasc Med. 2022 Sep 14;9:994502. doi: 10.3389/fcvm.2022.994502. eCollection 2022.

DOI:10.3389/fcvm.2022.994502
PMID:36187002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9518720/
Abstract

The development of transcatheter therapies to treat valvular heart diseases has changed the rules of the game, particularly in the case of aortic stenosis and mitral regurgitation. In the last years, the tricuspid valve has also been the focus of these percutaneous techniques for several reasons: (1) tricuspid regurgitation is a frequent disease associated with poor clinical outcomes in spite of medical treatment, leading to end-stage right ventricular heart failure, (2) surgical tricuspid valve repair or replacement has been the treatment of choice for patients with tricuspid valve disease, but high mortality rates for isolated surgical tricuspid valve intervention have been reported in the literature, and (3) most patients with tricuspid pathology are ultimately denied cardiac surgery because of their comorbidity burden. Thus, in this context the development of less invasive catheter-based therapies would be of high clinical relevance. The present review provides an overview regarding the framework of chronic tricuspid regurgitation transcatheter therapeutic options, summarizes the transcatheter systems under clinical use or clinical evaluation with their technical features, and describes the updated current evidence in this challenging and evolving field.

摘要

经导管治疗瓣膜性心脏病的发展改变了游戏规则,尤其是在主动脉瓣狭窄和二尖瓣反流的情况下。在过去几年中,三尖瓣也因多种原因成为这些经皮技术的焦点:(1)尽管进行了药物治疗,但三尖瓣反流仍是一种常见疾病,临床预后较差,会导致终末期右心室心力衰竭;(2)外科三尖瓣修复或置换一直是三尖瓣疾病患者的首选治疗方法,但文献报道孤立性外科三尖瓣干预的死亡率较高;(3)大多数患有三尖瓣病变的患者最终因合并症负担而被拒绝进行心脏手术。因此,在这种情况下,开发侵入性较小的基于导管的治疗方法具有高度的临床相关性。本综述概述了慢性三尖瓣反流经导管治疗选择的框架,总结了正在临床使用或临床评估中的经导管系统及其技术特点,并描述了在这个具有挑战性且不断发展的领域中的最新现有证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7ce/9518720/dc52c25c456b/fcvm-09-994502-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7ce/9518720/44e9b023b82a/fcvm-09-994502-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7ce/9518720/38ae59291247/fcvm-09-994502-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7ce/9518720/983450bcb7a6/fcvm-09-994502-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7ce/9518720/dc52c25c456b/fcvm-09-994502-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7ce/9518720/44e9b023b82a/fcvm-09-994502-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7ce/9518720/38ae59291247/fcvm-09-994502-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7ce/9518720/983450bcb7a6/fcvm-09-994502-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7ce/9518720/dc52c25c456b/fcvm-09-994502-g0004.jpg

相似文献

1
Transcatheter tricuspid valve interventions: Current status and future perspectives.经导管三尖瓣介入治疗:现状与未来展望。
Front Cardiovasc Med. 2022 Sep 14;9:994502. doi: 10.3389/fcvm.2022.994502. eCollection 2022.
2
Transcatheter Interventions for Tricuspid Valve Disease: What to Do and Who to Do It On.经导管三尖瓣疾病介入治疗:做什么和谁来做。
Can J Cardiol. 2021 Jul;37(7):953-967. doi: 10.1016/j.cjca.2020.12.029. Epub 2021 Jan 22.
3
Transcatheter Treatment of Valvular Heart Disease: A Review.经导管瓣膜病治疗:综述。
JAMA. 2021 Jun 22;325(24):2480-2494. doi: 10.1001/jama.2021.2133.
4
Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?经导管三尖瓣介入治疗的挑战与未来展望:沿用旧策略还是适应新机遇?
Eur J Heart Fail. 2022 Mar;24(3):442-454. doi: 10.1002/ejhf.2398. Epub 2021 Dec 21.
5
Emerging Transcatheter Therapies for Valvular Heart Disease: Focus on Mitral and Tricuspid Valve Procedures.用于心脏瓣膜病的新兴经导管治疗:聚焦二尖瓣和三尖瓣手术
Life (Basel). 2024 Jul 2;14(7):842. doi: 10.3390/life14070842.
6
7
Transcatheter tricuspid valve interventions: Current devices and associated evidence.经导管三尖瓣介入治疗:现有器械及相关证据。
Prog Cardiovasc Dis. 2021 Nov-Dec;69:89-100. doi: 10.1016/j.pcad.2021.11.007. Epub 2021 Nov 19.
8
Transcatheter Treatment of Tricuspid and Mitral Regurgitation: Similar Path, Different Stages.经导管三尖瓣和二尖瓣反流治疗:相似的路径,不同的阶段。
Cardiovasc Revasc Med. 2022 Jul;40:180-188. doi: 10.1016/j.carrev.2021.12.004. Epub 2021 Dec 9.
9
Transcatheter Tricuspid Valve Interventions: Landscape, Challenges, and Future Directions.经导管三尖瓣介入治疗:现状、挑战与未来方向。
J Am Coll Cardiol. 2018 Jun 26;71(25):2935-2956. doi: 10.1016/j.jacc.2018.04.031.
10
A focus on the percutaneous therapy of mitral and tricuspid regurgitation.聚焦二尖瓣和三尖瓣反流的经皮治疗。
Eur Heart J Suppl. 2023 Apr 21;25(Suppl B):B155-B160. doi: 10.1093/eurheartjsupp/suad095. eCollection 2023 Apr.

引用本文的文献

1
Transcatheter tricuspid valve replacement: will it prevail?经导管三尖瓣置换术:它会成为主流吗?
Front Cardiovasc Med. 2025 Apr 16;12:1562658. doi: 10.3389/fcvm.2025.1562658. eCollection 2025.
2
Caval Transcatheter Valve Implantation: An Alternate Transcatheter Approach to the Treatment of Severe Tricuspid Regurgitation.腔静脉经导管瓣膜植入术:一种治疗重度三尖瓣反流的替代经导管方法。
CASE (Phila). 2025 Jan 10;9(2):40-51. doi: 10.1016/j.case.2024.12.002. eCollection 2025 Feb.
3
Cost of illness of Heart Valve Diseases (HVDs): A real-world analysis in Italy.

本文引用的文献

1
Early and mid-term outcomes of transcatheter tricuspid valve repair: systematic review and meta-analysis of observational studies.经导管三尖瓣修复术的早期和中期结果:观察性研究的系统评价和荟萃分析
Rev Esp Cardiol (Engl Ed). 2023 May;76(5):322-332. doi: 10.1016/j.rec.2022.06.004. Epub 2022 Jun 2.
2
Transcatheter Tricuspid Valve Replacement With the EVOQUE System: 1-Year Outcomes of a Multicenter, First-in-Human Experience.EVOQUE 系统行经导管三尖瓣置换术:多中心、首例人体研究的 1 年结果。
JACC Cardiovasc Interv. 2022 Mar 14;15(5):481-491. doi: 10.1016/j.jcin.2022.01.280.
3
Complimentary Role of ICE and TEE During Transcatheter Edge-to-Edge Tricuspid Valve Repair With TriClip G4.
心脏瓣膜疾病(HVDs)的疾病成本:意大利的一项真实世界分析。
Glob Reg Health Technol Assess. 2025 Feb 19;12:34-42. doi: 10.33393/grhta.2025.3243. eCollection 2025 Jan-Dec.
4
Transcatheter Management of Tricuspid Regurgitation: A Review of Contemporary Evidence.经导管治疗三尖瓣反流:当代证据综述
Heart Int. 2024 Dec 18;18(2):24-36. doi: 10.17925/HI.2024.18.2.4. eCollection 2024.
5
Efficacy and Safety of Amiodarone and Propranolol in Pediatric Cardiology for Arrhythmia After Cardiac Surgery: A Retrospective Design Study.胺碘酮与普萘洛尔用于小儿心脏病学心脏术后心律失常的疗效与安全性:一项回顾性设计研究
Cureus. 2024 Nov 5;16(11):e73102. doi: 10.7759/cureus.73102. eCollection 2024 Nov.
6
Efficacy and Safety of Cardioband in Patients with Tricuspid Regurgitation: Systematic Review and Meta-Analysis of Single-Arm Trials and Observational Studies.Cardioband治疗三尖瓣反流患者的疗效和安全性:单臂试验和观察性研究的系统评价与荟萃分析
J Clin Med. 2024 Oct 25;13(21):6393. doi: 10.3390/jcm13216393.
7
Tricuspid Regurgitation Complicating Heart Failure: A Novel Clinical Entity.三尖瓣反流并发心力衰竭:一种新型临床实体。
Rev Cardiovasc Med. 2024 Sep 18;25(9):330. doi: 10.31083/j.rcm2509330. eCollection 2024 Sep.
8
Tricuspid regurgitation and heart failure: the fate of treated vs. untreated cohort in the percutaneous era.三尖瓣反流与心力衰竭:经皮治疗时代治疗组与未治疗组的转归
Eur Heart J Imaging Methods Pract. 2024 Aug 5;2(2):qyae080. doi: 10.1093/ehjimp/qyae080. eCollection 2024 Apr.
9
Regulatory science promotes the translation of transcatheter tricuspid valve repair/replacement devices.监管科学推动经导管三尖瓣修复/置换装置的转化。
Regen Biomater. 2024 Jul 18;11:rbae084. doi: 10.1093/rb/rbae084. eCollection 2024.
10
The Right Coronary Anatomy and Operative Topography of the Tricuspid Valve Annulus.三尖瓣环的右冠状动脉解剖结构及手术局部解剖学
J Cardiovasc Dev Dis. 2024 May 21;11(6):159. doi: 10.3390/jcdd11060159.
在使用TriClip G4进行经导管三尖瓣边缘对边缘修复术中ICE和TEE的互补作用
JACC Cardiovasc Interv. 2022 Mar 14;15(5):562-563. doi: 10.1016/j.jcin.2021.12.035. Epub 2022 Feb 9.
4
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery.TRI-SCORE:一种用于预测孤立性三尖瓣手术后院内死亡率的新风险评分。
Eur Heart J. 2022 Feb 12;43(7):654-662. doi: 10.1093/eurheartj/ehab679.
5
2021 ESC/EACTS Guidelines for the management of valvular heart disease.2021年欧洲心脏病学会/欧洲心胸外科学会瓣膜性心脏病管理指南。
Eur Heart J. 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395.
6
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.TAVR术后艾多沙班与维生素K拮抗剂用于心房颤动的比较
N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28.
7
Transcatheter Treatment of Secondary Tricuspid Regurgitation With Direct Annuloplasty: Results From a Multicenter Real-World Experience.经导管治疗继发三尖瓣反流的直接瓣环成形术:多中心真实世界经验的结果。
Circ Cardiovasc Interv. 2021 Aug;14(8):e010019. doi: 10.1161/CIRCINTERVENTIONS.120.010019. Epub 2021 Jul 30.
8
First-in-Human Percutaneous Circumferential Annuloplasty for Secondary Tricuspid Regurgitation.首例用于继发性三尖瓣反流的经皮环周瓣环成形术人体试验
JACC Case Rep. 2020 Nov 18;2(14):2176-2182. doi: 10.1016/j.jaccas.2020.08.032.
9
Current Status and Future Prospects of Transcatheter Mitral Valve Replacement: JACC State-of-the-Art Review.经导管二尖瓣置换术的现状与未来前景:JACC 观点述评。
J Am Coll Cardiol. 2021 Jun 22;77(24):3058-3078. doi: 10.1016/j.jacc.2021.04.051.
10
Short-Term Clinical Outcomes of Transcatheter Tricuspid Valve Repair With the Third-Generation MitraClip XTR System.第三代 MitraClip XTR 系统经导管三尖瓣修复的短期临床结果。
JACC Cardiovasc Interv. 2021 Jun 14;14(11):1231-1240. doi: 10.1016/j.jcin.2021.03.033.